BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Return
65.92%
This Quarter Return
+28.68%
1 Year Return
+65.92%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$131M
AUM Growth
+$4.53M
(+3.6%)
Cap. Flow
-$11.3M
Cap. Flow
% of AUM
-8.62%
Top 10 Holdings %
Top 10 Hldgs %
64.4%
Holding
34
New
7
Increased
2
Reduced
15
Closed
9
Top Buys
| 1 |
Protalix BioTherapeutics
PLX
|
+$8.97M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$8.24M |
| 3 |
INZY
Inozyme Pharma
INZY
|
+$3.53M |
| 4 |
Intellia Therapeutics
NTLA
|
+$3.49M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$2.82M |
Top Sells
| 1 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
+$11.5M |
| 2 |
OrthoPediatrics
KIDS
|
+$7.88M |
| 3 |
AnaptysBio
ANAB
|
+$4.88M |
| 4 |
Assembly Biosciences
ASMB
|
+$3.29M |
| 5 |
Regenxbio
RGNX
|
+$3.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
1
DELISTED
Epizyme, Inc
EPZM
| $10.1M | 7.7% |
930,467
-72,061
| -7% | -$783K |
|
2
PTC Therapeutics
PTCT
$4.85B
| $9.83M | 7.49% |
161,083
-12,462
| -7% | -$761K |
|
3
NeoGenomics
NEO
$1.03B
| $9.63M | 7.34% |
178,777
-13,894
| -7% | -$748K |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.59M | 7.31% |
1,388,136
-107,379
| -7% | -$742K |
|
|
5
Protalix BioTherapeutics
PLX
$144M
| $8.97M | 6.83% |
+2,470,332
| New | +$8.97M |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $8.83M | 6.73% |
72,484
-5,634
| -7% | -$686K |
|
|
LITS
7
Lite Strategy, Inc. Common Stock
LITS
$96.2M
| $8.46M | 6.45% |
160,297
+8,345
| +5% | +$441K |
|
|
8
BioCryst Pharmaceuticals
BCRX
$1.66B
| $8.24M | 6.28% |
+1,105,673
| New | +$8.24M |
|
9
Y-mAbs Therapeutics
YMAB
$390M
| $5.69M | 4.34% |
114,962
-8,063
| -7% | -$399K |
|
10
Insmed
INSM
$30.8B
| $5.15M | 3.92% |
154,562
-10,838
| -7% | -$361K |
|
11
Cytokinetics
CYTK
$6.12B
| $5.11M | 3.9% |
246,036
-18,823
| -7% | -$391K |
|
12
Apellis Pharmaceuticals
APLS
$3.14B
| $4.65M | 3.55% |
81,357
+4,553
| +6% | +$260K |
|
13
Aurinia Pharmaceuticals
AUPH
$1.68B
| $4.65M | 3.55% |
336,384
-25,999
| -7% | -$360K |
|
14
Korro Bio
KRRO
$289M
| $4.4M | 3.35% |
2,493
-190
| -7% | -$335K |
|
15
ADC Therapeutics
ADCT
$372M
| $4.03M | 3.07% |
125,850
-9,062
| -7% | -$290K |
|
|
INZY
16
DELISTED
Inozyme Pharma
INZY
| $3.53M | 2.69% |
+170,796
| New | +$3.53M |
|
|
17
Intellia Therapeutics
NTLA
$1.23B
| $3.49M | 2.66% |
+64,079
| New | +$3.49M |
|
18
Fulcrum Therapeutics
FULC
$379M
| $3.18M | 2.43% |
271,926
-19,719
| -7% | -$231K |
|
19
Crinetics Pharmaceuticals
CRNX
$3.2B
| $3.16M | 2.41% |
224,129
-17,149
| -7% | -$242K |
|
|
20
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.82M | 2.15% |
+161,628
| New | +$2.82M |
|
21
Merus
MRUS
$5.26B
| $2.29M | 1.75% |
130,683
-9,493
| -7% | -$166K |
|
|
GTHX
22
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $2.12M | 1.61% |
117,708
-110,889
| -49% | -$2M |
|
|
TECX
23
Tectonic Therapeutic, Inc. Common Stock
TECX
$332M
| $2.03M | 1.55% |
+12,143
| New | +$2.03M |
|
24
Black Diamond Therapeutics
BDTX
$185M
| $1.12M | 0.85% |
+34,891
| New | +$1.12M |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$367M
| $134K | 0.1% |
15,006
| – | – |
|